Harbor Mid Cap Value ETF (EPMV)

On our desk, looking at the EPMV order book is tough. With a market cap hovering around $4.5 million to $4.73 million and average daily volume failing to clear 70-80 shares, execution risk is high. The wider bid-ask spread can instantly erase any tactical alpha you pick up from bottom-up value selection. Until liquidity deepens drastically, institutions cannot touch this instrument in size.

As a risk manager reviewing EPMV's risk metrics, the 1-year beta of 0.84 looks appealing on paper compared to category norms. However, Morningstar's low 3-year and 5-year return-versus-category ratings flag that reduced volatility hasn't generated efficient risk-adjusted returns. Plus, with a portfolio P/E of 15.53x sitting above category averages, we aren't even getting deep-value discounts for the operational illiquidity.

From a quantitative screening standpoint, EPMV's reliance on EARNEST Partners' bottom-up fundamental research sounds solid in theory. Yet, the 0.88% expense ratio is roughly 3 to 4 times higher than standard passive mid-cap value alternatives. Without a multi-year track record since its May 2025 launch, paying that active fee premium requires a leap of faith that the current portfolio construction simply hasn't proven.

Evaluating the fund's asset-gathering capability, EPMV's total net assets lingering near $4 million represent a critical mass issue. Even though Harbor Capital Advisors brings strong institutional infrastructure and 25+ years of EARNEST Partners screening expertise, an ETF of this size faces structural closure or liquidity liquidation risks if organic inflows do not accelerate past the early-stage threshold.

Tracking market sentiment over the past quarter, sector allocation was a clear drag for EPMV. Overweight postures in Financials and Consumer Discretionary, alongside an underweight in Energy and Utilities, acted as direct headwinds. When Oil and Gas surged nearly 37% on commodity moves rather than fundamentals, EPMV's limited exposure kept it from capturing that cyclical upside, leading to its Q1 2026 underperformance against the Russell Midcap Value Index.